Pdt Partners, LLC Supernus Pharmaceuticals, Inc. Transaction History
Pdt Partners, LLC
- $1.02 Billion
- Q3 2024
A detailed history of Pdt Partners, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 37,110 shares of SUPN stock, worth $1.35 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
37,110Holding current value
$1.35 Million% of portfolio
0.11%Shares
8 transactions
Others Institutions Holding SUPN
# of Institutions
282Shares Held
60.9MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$379 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$224 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$186 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$105 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$96 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.95B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...